Blog Category





Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Aw...

August 29th, 2019

The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which advance solutions in the prevention, management or care of canc...

Read article



Helsinn to co-support a satellite symposium on current and emerging treatments o...

June 12th, 2019

Symposium will explore the landscape and potential development of treatment options for AML.

Read article

Helsinn Group supports two events with the International Society for Cutaneous L...

June 7th, 2019

Cutaneous Lymphoma Meeting will update on latest developments in the field Folliculotropic Mycosis Fungoides Work Group will review recent expert work...

Read article




Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Onco...

March 19th, 2019

Mihir Shah of UE LifeSciences Inc. has been selected as the winner of the 2019 Lyfebulb-Helsinn Innovation Award in Oncology Pierluigi Paracchi of Gen...

Read article

Helsinn initiates two new global Phase III studies with anamorelin

March 7th, 2019

Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung cancer (NSCLC) and...

Read article


Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation...

February 27th, 2019

The Award recognizes Patient Entrepreneurs’ innovations for cancer and cancer supportive care using therapeutics, diagnostics, medical devices or heal...

Read article